Johnson & Johnson Newsroom

Express News | Johnson & Johnson Shares up 0.4%

Breakings04:38

Express News | Cigna Shares Pare Gains, Last up 0.2%; Wall Street Journal Reports Johnson & Johnson Has Sued Divisions of Cigna

Breakings04:37

"J&J Accuses Big Health Insurer of Helping Drain Its Drug Copay Funds; Pharmaceutical Company Claims Cigna Units Worked With SaveOn and Caused It to Pay More Than $100 Million in Copay Assistance Than It Would Have Otherwise" - WSJ

Benzinga04:33

Johnson & Johnson Options Trading: A Deep Dive Into Market Sentiment

Benzinga02:46

Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report

Benzinga01:15

ACTION Centers Collaborate With Johnson & Johnson MedTech to Secure FDA Labeling for Impella Support System in Pediatric Patients

PR Newswire00:43

Johnson & Johnson's (NYSE:JNJ) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Yahoo FinanceDec 13 21:00

RBC Capital Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Maintains Target Price $181

Futu NewsDec 13 20:33 · Ratings

Johnson & Johnson to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

BusinesswireDec 13 05:30

Jim Cramer Says This CEO 'Built An Amazing Company,' Recommends Buying Netflix

BenzingaDec 12 21:55

U.S. FDA Expands Indication for Impella Heart Pumps to Treat Pediatric Patients

PR NewswireDec 12 21:30

Today's Analyst Rating | Citi Cuts Its Price Target Cut on Johnson & Johnson to $175, Deutsche Bank Upgrades Coca-Cola to Buy

Dec 12, Wall Street analysts have updated their stock ratings today including $Johnson & Johnson(JNJ.US)$ and $Coca-Cola(KO.US)$.

Futu NewsDec 12 21:00 · Ratings

Bank of America resumes coverage of Johnson & Johnson with a Target Price of $166.

Gelonghui, December 12 | Bank of America: Resumes coverage of Johnson & Johnson, giving it a "neutral" rating, with a Target Price of $166. (Gelonghui)

Gelonghui FinanceDec 12 16:16 · Ratings

Latest research results on Johnson & Johnson (JNJ.US) CAR-T therapy announced

Johnson & Johnson (JNJ.US) recently announced the latest research results of the phase 3 clinical trial CARTITUDE-4.

Zhitong FinanceDec 12 08:03

Express News | Citigroup has lowered the Target Price for Johnson & Johnson from $185.00 to $175.00.

BreakingsDec 12 03:26

Citi Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Cuts Target Price to $175

Futu NewsDec 11 20:31 · Ratings

Express News | J&J : Citigroup Cuts Target Price to $175 From $185

BreakingsDec 11 20:18

Investors in Johnson & Johnson (NYSE:JNJ) Have Unfortunately Lost 4.4% Over the Last Three Years

Simply Wall StDec 11 19:49

Why Is Johnson & Johnson (JNJ) Among the Best Cosmetic Surgery and Aesthetics Stocks to Invest In Now?

Yahoo FinanceDec 11 12:20

BofA Restarts Coverage of 11 Large-cap Biopharmas

Seeking AlphaDec 11 06:01